Breye Therapeutics

Danish ophthalmology drug developer advancing orally administered danegaptide and P2X7 antagonist candidates.

View on the globe

$76.7MEquity raised in 2025–20262025 — · 2026 $76.7M · 1 equity round
$76.7MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 29 Sep 2026 to 29 Sep 2026, $76.7M equity disclosed. Earlier rounds exist but are not sourced.29 Sep 2026: Series A, $76.7M$1M$3M$10M$30M$100MEarlier rounds exist but are not sourced yet← earlier rounds not sourcedQ2Q3Q42027Q2Equity round29 Sep 2026 · Series A · $76.7M · led by Mission BioCapital, Novo HoldingsSeries A · $76.7M
Funding history: 1 round from 29 Sep 2026 to 29 Sep 2026, $76.7M equity disclosed. Earlier rounds exist but are not sourced.29 Sep 2026: Series A, $76.7M$1M$3M$10M$30M$100MEarlier rounds exist but are not sourced yetearlier rounds not sourcedQ2Q3Q42027Q2Equity round29 Sep 2026 · Series A · $76.7M · led by Mission BioCapital, Novo Holdings$76.7M

Funding history 1 round · 1 source

Earlier rounds not yet sourced. Breye Therapeutics raised before 29 Sep 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series A
    Amount$76.7MEUR 67.5M
    Post-money—
    ✓ Confirmed
    Lead
    Mission BioCapital, Novo Holdings
    Also
    Sound Bioventures, Ljungström, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, Pappas Capital
    Note
    Company release: EUR 67.5M Series A, co-led by Mission BioCapital (new investor) and Novo Holdings (existing). USD converted at the ECB reference rate for 29 Sep 2026 (1 EUR = 1.1355 USD, approximate). Valuation not disclosed (no pre- or post-money figure). Release dateline is Copenhagen; the company's registered address is Hørsholm. Pulse2 (2 Oct) and Caplight (9 Feb 2026) not used. Ljungström named as in the release (family office).
    Sources
  2. Earlier rounds not yet sourced

Investors 9

  • Mission BioCapital1
  • Novo Holdings1
  • Catalyze Capital
  • EIFO
  • Innovestor Life Science
  • Ljungström
  • Modi Ventures
  • Pappas Capital
  • Sound Bioventures

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Breye Therapeutics and its logo are trademarks of their owners, used here for identification only.